Devised and executed comprehensive engagement strategies which fostered partnerships and relationships with key Patient Advocacy Groups (PAG's) and professional organizations for pre-and post-launch of Inotersen/Tegsedi®. Led the implementation of holistic company philosophy for patient marketing and patient engagement to bring the patient perspective and need underscore patient-centric mission and transforming care.➥Provide counsel to internal stakeholders on the strategies and tactics that can be employed to advance business interests.➥Established integrity-based relationships spanning PAG, professional and company in rare disease space with small, committed biotech by providing continuous disease education and planning for future. ➥Infused the patient voice into the everyday operations of the company, driving leadership and stakeholders to remain patient centric on corporate strategies and key decisions. ➥Led relationship development with key advocacy and professional societies to ensure ongoing collaboration based on mutual respect and patient focused objectives ➥Defined, developed and conducted patient advisory boards and patient advocacy meetings/summits for marketing disease education materials.➥Developed and implemented 5 surveys comparing HCP and patient perspectives and linguistics for publication.

Leveraged extensive experience and knowledge to provide strategic, tactical, patient marketing, and patient advocacy plans, agency selections, and process improvements to companies ranging from small biotech start-ups to large corporations. Coordinated patient speakers for branded and unbranded programs.➥ Served as speaker at patient-centered events.➥Patient journey mapping to inform materials and leadership.

Diagnostic testing firm specializing in oral fluid and blood rapid point of care technology. Communicated and collaborated with grassroots advocacy communities raising patient awareness of point of care testing. Partnered with Federally Qualified Health Centers (FQHC), Public Health Organizations, and PAG’s to develop and conduct testing programs, including hands-on testing. Steered implementation for rebuilding phase of key marketing programs seeking market expansion. Coordinated multiple enterprise-wide business and marketing segments including manufacturing and end customer. ➥Forecasted net revenue growth over 5 years after identifying four testing partnership initiatives.➥Implemented target audience initiative for 15,000 new HCPs, which increased patient count by 21% and was complete with product training, program implementation, and patient activation.➥Delivered 35% growth in 4 consecutive quarters.➥Spearheaded OraQuick HCV® launch including strategy, planning and execution, composing messaging, internal training, and collateral development.➥Increased recruitment by 33% through working internally to identify new methods for finding patients.➥Expanded market by identifying and testing patients waiting for new and more efficacious HCV therapies.

Recruited and developed treatment advocates in ultra-orphan disease to develop marketing materials and for internal, external, and public affairs programs, allowing for regulatory-compliant, actual patient stories. increased disease awareness. Oversaw cross-functional team in developing and executing strategy, tactical plans, and opportunity assessments for 2nd indication launch.➥Participated and collaborated in tactical plan development, patient marketing materials, strategy and execution.➥Achieved more than 20% growth for 3 consecutive quarters.➥Trained and utilized patient advocates on rare disease impacts for lobbying and testifying before Congress.➥Increased unmet patient needs awareness which generated new prescribers and retained existing customers nationally adapting for utilization within US.➥Provided P&L oversight of global budget and consistently maintained less than <5% delta. ➥Developed and directed strategic planning and implementation of key patient marketing to launch Soliris® by working cross-functionally and managing enterprise-wide business and patient aspects.

Steered patient promotional team and managed budget to support the launch of Actemra(tocilizumab) for rheumatoid arthritis (RA). Defined and directed implementation of strategic plans for consumer audiences that included disease education and branded conversion with compliance management. ➥Launched 3 indications of Pegasys®, virology and Hepatitis C➥Built strong relationships with advocacy organizations and professional societies.➥Drove digital assessment and integration to ensure brand remained innovative and utilized new technologies. ➥Engaged with senior management, commercial organizations, and agency partners to effectively communicate marketing direction.